FDA authorizes drug combination to treat hospitalized COVID-19 patients

by on

FDA authorizes drug combination to treat hospitalized COVID-19 patients
Damareus Barbour CA
Nov 23, 2020

The Food and Drug Administration yesterday authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation. Baricitinib is currently FDA-approved to treat rheumatoid arthritis, but is not authorized or approved as a stand-alone treatment for COVID-19. Although evaluation of the combination therapy’s safety and effectiveness continues, FDA said the median COVID-19 recovery time for baricitinib plus remdesivir was seven days versus eight days for placebo plus remdesivir, among other benefits, in a clinical trial of hospitalized COVID-19 patients.

Headline

FDA authorizes drug combination to treat hospitalized COVID-19 patients
Damareus Barbour CA
Nov 23, 2020

The Food and Drug Administration yesterday authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation. Baricitinib is currently FDA-approved to treat rheumatoid arthritis, but is not authorized or approved as a stand-alone treatment for COVID-19. Although evaluation of the combination therapy’s safety and effectiveness continues, FDA said the median COVID-19 recovery time for baricitinib plus remdesivir was seven days versus eight days for placebo plus remdesivir, among other benefits, in a clinical trial of hospitalized COVID-19 patients.

COVID-19: Vaccines and Therapeutics

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: